88 results
424B5
BLPH
Bellerophon Therapeutics, Inc.
31 May 23
Prospectus supplement for primary offering
4:40pm
submitted for federal funding, through Biomedical Advanced Research and Development Authority, or BARDA, and National Institutes of Health, or NIH, to support … , but not limited to, our internal research and development programs and the development of new programs, general working capital and possible future
8-K
EX-99.1
BLPH
Bellerophon Therapeutics, Inc.
15 May 23
Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results
4:54pm
loss of $5.6 million, or $(0.59) per basic and diluted share, in the first quarter ended March 31, 2022.
Research and development expenses for the first … of the Company’s net operating losses and research and development credits under the State of New Jersey’s Technology Business Tax Certificate Transfer Program
8-K
EX-99.1
don iubitur
31 Mar 23
Bellerophon Provides Clinical Program Update and Reports Full-Year 2022 Financial Results
8:29am
8-K
EX-99.1
ix1tqi17rn
14 Nov 22
Bellerophon Provides Clinical Program Update and Reports Third Quarter 2022 Financial Results
9:12am
8-K
EX-99.1
p7xl rqqvqh82
15 Aug 22
Bellerophon Provides Clinical Program Update and Reports Second Quarter 2022 Financial Results
8:41am
8-K
EX-99.1
4ten4uashm j0p32d1
11 May 22
Bellerophon Provides Clinical Program Update and Reports First Quarter 2022 Financial Results
8:34am
8-K
EX-99.1
07e1hl rv1pnn
31 Mar 22
Bellerophon Provides Clinical Program Update and Reports Full-Year 2021 Financial Results
4:04pm
8-K
EX-99.1
i4ol9fbw
15 Nov 21
Bellerophon Provides Clinical Program Update and Reports Third Quarter 2021 Financial Results
9:02am
8-K
EX-99.1
kl404lc
5 Aug 21
Bellerophon Provides Clinical Program Update and Reports Second Quarter 2021 Financial Results
8:29am